It’s been a busy week for Repare Therapeutics. On Tuesday, the cancer drug developer struck up an alliance with Bristol Myers Squibb (NYSE: [[ticker:BMY]]) that pays $65 million now and as much as $3 billion later, depending on the progress made in coming years. On Friday, Repare filed for an IPO that could bring in … Continue reading “After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO”
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
AbbVie Wins First FDA Approval of Drug to Treat Uterine Fibroid Bleeds
An AbbVie drug that treats pain in the uterus has notched an additional FDA approval for addressing heavy menstrual bleeding associated with uterine fibroids. The regulatory decision Friday covers that drug, elagolix, combined with estrogen and progestin in a capsule that North Chicago, IL-based AbbVie (NYSE: [[ticker:ABBV]]) plans to market as Oriahnn. Elagolix (Orilissa) was … Continue reading “AbbVie Wins First FDA Approval of Drug to Treat Uterine Fibroid Bleeds”
Ipsen Taps Sanofi’s Vaccines Executive David Loew for CEO Role
David Loew, the top Sanofi (NYSE: [[ticker:SNY]]) executive for the pharmaceutical giant’s vaccines division, is leaving to become Ipsen’s new CEO. He is also joining the board of directors of Ipsen, a developer of drugs for oncology, neurological disorders, and rare diseases. Loew’s experience includes roles at Coopers & Lybrand, Hewlett Packard (NYSE: [[ticker:HPQ]]), and … Continue reading “Ipsen Taps Sanofi’s Vaccines Executive David Loew for CEO Role”
Immunomedics President & CEO Harout Semerjian Steps Down
Six weeks after starting as president and CEO of Immunomedics (NASDAQ: [[ticker:IMMU]]), Harout Semerjian has resigned. In a statement, the Morris Plains, NJ-based company said the decision was precipitated by the “significant logistical obstacles presented by the COVID-19 pandemic.” Semerjian was named the new CEO of Immunomedics in early April, joining from France-based Ipsen, where … Continue reading “Immunomedics President & CEO Harout Semerjian Steps Down”
Gilead’s Delaney Jumps to Assembly Bio as Chief Scientific Officer
The addition of Gilead Sciences veterans to the Assembly Biosciences (NASDAQ: [[ticker:ASMB]]) C-suite continues with the hiring of William Delaney as chief scientific officer of virology. Delaney worked at Gilead (NASDAQ: [[ticker:GILD]]) for more than 20 years, most recently as executive director of biology. At South San Francisco-based Assembly, he will succeed Richard Colonno, who … Continue reading “Gilead’s Delaney Jumps to Assembly Bio as Chief Scientific Officer”
Former Aimmune Exec Stephen Dilly Named Sierra Oncology’s New CEO
Sierra Oncology (NASDAQ: [[ticker:SRRA]]) has appointed Stephen Dilly to serve as its president and CEO starting June 1. He is also joining the Vancouver, BC-based company’s board of directors. Dilly retired as CEO of Aimmune Therapeutics (NASDAQ: [[ticker:AIMT]]) in 2018. His experience also includes positions at Genentech, Chiron BioPharma, and SmithKline Beecham. Sierra acquired its … Continue reading “Former Aimmune Exec Stephen Dilly Named Sierra Oncology’s New CEO”
Gilead Gains Foothold in Solid Tumors With $375M, 10-Year Arcus Bio Pact
With the year’s biggest oncology conference days away, Gilead Sciences is signaling now what its cancer immunotherapy pipeline could look like in the years to come. The drug maker is entering a partnership with Arcus Biosciences that spans the biotech’s four clinical-stage compounds, plus additional programs that may come out of the 10-year alliance. The … Continue reading “Gilead Gains Foothold in Solid Tumors With $375M, 10-Year Arcus Bio Pact”
COVID-19 Sparks New Opportunities for Digital Health Companies
Clinicians and regulators are rethinking how healthcare is provided amid precautions prompted by COVID-19. In-person physician visits don’t fit within the physical distancing guidelines that are now the new normal. New technology presents alternatives. As a digital therapeutics startup, Akili Interactive finds itself thrust in the midst of these changes. The Boston company has developed … Continue reading “COVID-19 Sparks New Opportunities for Digital Health Companies”
Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq
COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too. But the biotech sector is defying the pandemic with crossover financings and freshly minted public companies. On Friday, three firms added their names to the list of life science companies preparing to join the public markets. Gene therapy company Generation … Continue reading “Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq”
Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More
As the nation started to reopen this week following two months of closed businesses and stay-at-home orders, public health officials and economists cautioned that society won’t truly return to anything resembling a pre-pandemic normal without a COVID-19 vaccine. Moderna (NASDAQ: [[ticker:MRNA]]) moved one step closer to filling that need with the release of preliminary Phase … Continue reading “Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More”
Sunovion Drug Gets FDA Nod for Treating Parkinson’s “Off” Episodes
The FDA on Thursday approved a Sunovion Pharmaceuticals treatment for Parkinson’s disease, giving patients a new way to take an old drug. The Sunovion product, Kynmobi, is a formulation of apomorphine hydrochloride, a drug that treats “off” episodes experienced by Parkinson’s patients. These are times when the standard of care drug, levodopa, wears off and … Continue reading “Sunovion Drug Gets FDA Nod for Treating Parkinson’s “Off” Episodes”
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
HotSpot Therapeutics set out two years ago to find new ways to address elusive disease targets. It now has molecules on the path to becoming potential medicines backed by a fresh $65 million. The Series B round of funding announced Thursday was led by SR One, the venture investment arm of GlaxoSmithKline (NYSE: [[ticker:GSK]]). The … Continue reading “HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic”
Applied Molecular Plots IPO to Back Transport of Biologic Drugs to Gut
The human gut hosts a hub of activity spanning the immune system, the nervous system, and more. But drugging this nexus comes with challenges. Applied Molecular Transport is developing biologic drugs that use a cell’s own mechanisms to get a therapy to a target and the biotech is now planning to tap the public markets … Continue reading “Applied Molecular Plots IPO to Back Transport of Biologic Drugs to Gut”
Merck Spinoff Organon Taps Ex-Allergan Execs Walsh, Stahler for C-Suite
Organon, a company spinning off from Merck (NYSE: [[ticker:MRK]]), is filling out its C-suite with the appointment of two new executives. Matthew Walsh is joining as chief financial officer; Rachel Stahler as chief information officer. Both come from Allergan, which was recently acquired by AbbVie (NYSE: [[ticker:ABBV]]). Walsh was Allergan’s executive vice president and CFO … Continue reading “Merck Spinoff Organon Taps Ex-Allergan Execs Walsh, Stahler for C-Suite”
Teva’s Tushar Shah Joins Liquidia as Chief Medical Officer
Liquidia Technologies (NASDAQ: [[ticker:LQDA]]) has appointed Tushar Shah to serve in the newly created role of chief medical officer. Shah is joining Research Triangle Park, NC-based Liquidia from Teva Pharmaceutical (NYSE: [[ticker:TEVA]]), where he was head of global specialty clinical development. Liquidia develops drugs using proprietary nanoparticle technology intended to improve the delivery of medicines. … Continue reading “Teva’s Tushar Shah Joins Liquidia as Chief Medical Officer”
Rallybio Lands $145M to Alter Course of FNAIT and More Rare Diseases
One of the risks to a newborn’s life comes from the mother’s immune system. It attacks the platelets of the fetus, depleting these blood-clotting cells and risking uncontrollable bleeding in the baby. Rallybio aims to develop the first FDA-approved treatment for this rare condition and the startup has raised $145 million to bring that drug, … Continue reading “Rallybio Lands $145M to Alter Course of FNAIT and More Rare Diseases”
Early COVID-19 Vaccine Data Sets Up Moderna for Next Stages of Testing
Moderna’s experimental COVID-19 vaccine is showing signs it can elicit antibodies at levels comparable to those found in the blood of dozens of patients who have recovered from the infectious disease, according to early results released Monday. The company is now preparing to quickly bring its vaccine candidate into the next stages of human testing. … Continue reading “Early COVID-19 Vaccine Data Sets Up Moderna for Next Stages of Testing”
ADC’s $233M IPO Brings It to NYSE With Cancer Drug Launch on Horizon
ADC Therapeutics is making its public markets debut, raising about $233 million six months after the cancer drug developer withdrew its initial IPO plans. Not only did Épalinges, Switzerland-based ADC go through with the stock offering this time around, it was also able to boost the deal’s size—not once, but three times. On Monday, the … Continue reading “ADC’s $233M IPO Brings It to NYSE With Cancer Drug Launch on Horizon”
From Overseas, Legend Biotech and Calliditas Therapeutics Eye the Nasdaq
Legend Biotech, a cancer cell therapy developer with roots in China, is preparing for a US stock exchange listing as its lead candidate keeps pace in the race for a multiple myeloma drug that addresses a new molecular target. The drug, known as JNJ-4528, is being developed in partnership with Johnson & Johnson (NYSE: [[ticker:JNJ]]) … Continue reading “From Overseas, Legend Biotech and Calliditas Therapeutics Eye the Nasdaq”
Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System
It may seem like an unlikely link but the body’s response to arthritis may hold answers for better cancer drugs, says Luis Voloch, chief technology officer of startup Immunai. Immune cells respond to both conditions, but in different ways. Insights into the response for one disease could inform the treatment of the other, he says. … Continue reading “Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System”
BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info
Bristol Myers Squibb’s bid to win FDA approval for its multiple myeloma cell therapy has hit a detour. The FDA declined to review the experimental treatment and has instead asked the company to provide more information. Bristol (NYSE: [[ticker:BMY]]) announced Wednesday that it received a “refusal to file” letter for the experimental therapy, idecabtagene vicleucel … Continue reading “BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info”
Pliant Pushes Forward With IPO Plans to Back Fibrosis Drug Studies
Pliant Therapeutics has a pipeline of experimental fibrosis treatments and a research alliance with Novartis. Now the biotech is preparing an IPO to raise cash to advance its clinical-stage programs. In paperwork filed with securities regulators, Pliant set an $86 million IPO target. That amount is a placeholder figure as the South San Francisco-based biotech … Continue reading “Pliant Pushes Forward With IPO Plans to Back Fibrosis Drug Studies”
Celsius Therapeutics Names Jeanne Magram Chief Scientific Officer
Celsisus Therapeutics has appointed Jeanne Magram to serve as the Cambridge, MA-based drug developer’s chief scientific officer. She was most recently the CSO of Quentis Therapeutics. Magram’s experience also includes positions at Northern Biologics, Pfizer (NYSE: [[ticker:PFE]]), Boehringer Ingelheim, OSI Pharmaceuticals, and Roche. Celsius is using single-cell genomics to develop new treatments for cancer and autoimmune … Continue reading “Celsius Therapeutics Names Jeanne Magram Chief Scientific Officer”
Bolt Bio Picks Sunesis’s William Quinn as Chief Financial Officer
Bolt Biotherapeutics has appointed William Quinn to serve as its chief financial officer, the same position he held most recently at Sunesis Pharmaceuticals (NASDAQ: [[ticker:SNSS]]). Quinn’s experience also includes roles at Bullet Biotechnology and Jazz Pharmaceuticals (NASDAQ: [[ticker:JAZZ]]). Preclinical-stage Bolt Bio is developing a new class of cancer immunotherapies called immune-stimulating antibody conjugates. Last year, … Continue reading “Bolt Bio Picks Sunesis’s William Quinn as Chief Financial Officer”
MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021
An experimental MyoKardia drug developed to treat an inherited cardiovascular condition that restricts blood flow is showing it can improve on the symptoms of this condition as well as the heart’s ability to function. MyoKardia (NASDAQ: [[ticker:MYOK]]) is testing its drug, mavacamten, in patients who have obstructive hypertrophic cardiomyopathy (HCM), a hardening and thickening of … Continue reading “MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021”
Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug
[Updated, 5/11/2020, 10:03 a.m. See below.] Eli Lilly received accelerated FDA approval Friday for a drug that treats advanced cancers carrying a certain genetic signature. It’s the latest targeted cancer therapy to pass the regulatory bar and the first that addresses tumors characterized by aberrations in one particular gene. The gene in question, RET, produces … Continue reading “Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug”
Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More
Alexion Pharmaceuticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness to open the corporate checkbook to accomplish that goal. Last October, Alexion (NASDAQ: [[ticker:ALXN]]) struck a $930 million deal to acquire Achillion Pharmaceuticals, a biotech whose lead drug complements the Boston company’s … Continue reading “Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More”
Ayala’s IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs
Ayala Pharmaceuticals has two clinical-stage cancer drugs licensed from Bristol Myers Squibb. Now it has $55 million to take those drugs further than the pharmaceutical giant did. On Thursday evening, Ayala priced its IPO, which consisted of 3.7 million shares sold for $15 each. That price was the midpoint of the targeted $14 to $16 … Continue reading “Ayala’s IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs”
Gemini Therapeutics Names Ex-Achillion Exec Marc Uknis Chief Medical Officer
Gemini Therapeutics has appointed Marc Uknis to serve as its chief medical officer. Uknis was most recently a vice president at Achillion, which was acquired by Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]) last year. His experience also includes positions at ViroPharma and CSL Behring. Cambridge, MA-based Gemini launched in 2017 to develop treatments for age-related macular degeneration. … Continue reading “Gemini Therapeutics Names Ex-Achillion Exec Marc Uknis Chief Medical Officer”
Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation
As cancer research reveals the genetic basis of the disease, pharmaceutical companies are pursuing targeted therapies that address certain groups of patients. One such drug from Novartis won FDA approval Wednesday, making it the first therapy cleared by the agency to treat patients whose non-small cell lung cancer (NSCLC) carries a certain genetic mutation. The … Continue reading “Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation”
Kezar Life Sciences Taps Noreen Roth Henig as Chief Medical Officer
Kezar Life Sciences (NASDAQ: [[ticker:KZR]]) has appointed Noreen Roth Henig to serve as its chief medical officer, the same role she held most recently at Breath Therapeutics. Breath was acquired by Zambon last year for €140 million up front. Henig’s experience also includes roles at ProQR Therapeutics and Gilead Sciences (NASDAQ: [[ticker:GILD]]). South San Francisco-based … Continue reading “Kezar Life Sciences Taps Noreen Roth Henig as Chief Medical Officer”
Ventus Launches With $60M to Shine Light on Innate Immune System Drugs
The innate immune system has become a hot area for drug development, and for good reason. As the body’s first line of defense, its function (or dysfunction) plays a role in many diseases. The problem, says Ventus Therapeutics CEO Marcelo Bigal, is that drug developers have been working in the dark. Scientists don’t know the … Continue reading “Ventus Launches With $60M to Shine Light on Innate Immune System Drugs”
Alexion Pharma Boosts Blood Drug Lineup With $1.4B Deal for Portola
Alexion Pharmaceuticals has agreed to buy Portola Pharmaceuticals in a $1.4 billion deal that brings it a first-in-class therapy for treating life-threatening bleeding. According to financial terms announced Tuesday, Boston-based Alexion (NASDAQ: [[ticker:ALXN]]) will pay $18 for each outstanding share of Portola (NASDAQ: [[ticker:PTLA]]). That price is a a nearly 132 percent premium to Monday’s … Continue reading “Alexion Pharma Boosts Blood Drug Lineup With $1.4B Deal for Portola”
Arrowhead Pharma’s Chief Operating Officer Bruce Given Retires
Bruce Given, chief operating officer and head of R&D for Arrowhead Pharmaceuticals (NASDAQ: [[ticker:ARWR]]), has retired. Given’s responsibilities are being divided among the company’s chief medical officer, chief scientific officer, and chief commercial officer. Given, who joined Arrowhead in 2011, will serve as an advisor to the Pasadena, CA, company for at least one year. … Continue reading “Arrowhead Pharma’s Chief Operating Officer Bruce Given Retires”
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
The genetic mutations that cause epilepsy don’t stop there. Praxis Precision Medicines CEO Marcio Souza says research also links these genes to other neurological conditions. The biotech startup is turning that research into new neuro drugs and it’s coming out of stealth to share details about its science and its pipeline, which already has two … Continue reading “Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs”
Pfizer Pays Valneva $130M for a Bite at a Lyme Disease Vaccine
If you’re looking for a Lyme disease vaccine, you can choose from among several—for your dog. A vaccine for humans hasn’t been available for years and few companies have tried to fill that void. Valneva has advanced its Lyme vaccine candidate to mid-stage clinical testing, and the company now has the help of drug giant … Continue reading “Pfizer Pays Valneva $130M for a Bite at a Lyme Disease Vaccine”
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
Lyra Therapeutics, a biotech company developing a new way to treat your persistently runny nose, has raised $56 million in its public markets debut. Late Thursday, Lyra offered 3.5 million shares priced at $16 apiece, which was the high end of its projected $14 to $16 price range. Those shares are expected to begin trading … Continue reading “Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses”
Goldfinch Bio Adds Kyle Kuvalanka, Lori Rudolph-Owen to C-Suite
Goldfinch Bio has appointed Kyle Kuvalanka to serve as chief financial and chief operating officer. His experience includes positions at Syros Pharmaceuticals, Blueprint Medicines (NASDAQ: [[ticker:BPMC]]), and Takeda Pharmaceutical (NYSE: [[ticker:TAK]]). In other moves, Cambridge, MA-based Goldfinch promoted Lori Rudolph-Owen to chief development officer. She joined the company in 2018 as senior vice president of … Continue reading “Goldfinch Bio Adds Kyle Kuvalanka, Lori Rudolph-Owen to C-Suite”
Intellia Therapeutics Taps Semma’s Lebwohl as Chief Medical Officer
Intellia Therapeutics (NASDAQ: [[ticker:NTLA]]) has appointed David Lebwohl to serve as executive vice president and chief medical officer. He is joining the Cambridge, MA-based gene-editing therapies company from Semma Therapeutics, where he also held the chief medical officer position. Lebwohl’s prior experience includes positions at Novartis (NYSE: [[ticker:NVS]]) and Bristol Myers Squibb (NYSE: [[ticker:BMY]]). Intellia is … Continue reading “Intellia Therapeutics Taps Semma’s Lebwohl as Chief Medical Officer”
Radius Health CEO Hoeiland Steps Down, Martin Named Successor
Radius Health (NASDAQ: [[ticker:RDUS]]) president and CEO Jesper Hoeiland has stepped down, the company announced Tuesday. In a statement, Hoeiland said that after nearly 25 years abroad, he and his wife decided to return to Denmark to be closer to family and friends. According to a securities filing, he will serve as a paid advisor … Continue reading “Radius Health CEO Hoeiland Steps Down, Martin Named Successor”
Forma Therapeutics Taps Ex-Seres Exec Cook as Chief Scientific Officer
Forma Therapeutics has appointed David Cook to serve as its senior vice president and chief scientific officer. Cook’s experience includes senior roles at Seres Therapeutics (NASDAQ: [[ticker:MCRB]]), the International AIDS Vaccine Initiative, Anza Therapeutics, and Cerus Corporation. Watertown, MA-based Forma develops drugs for rare blood diseases and cancers. The company’s most advanced program, olutasidenib, is … Continue reading “Forma Therapeutics Taps Ex-Seres Exec Cook as Chief Scientific Officer”
Supernus Makes a Parkinson’s Play With $300M Deal for US WorldMeds Drugs
Supernus Pharmaceuticals is expanding its central nervous system (CNS) drug lineup through a deal to acquire four US WorldMeds products with applications in Parkinson’s disease. The products, three of them already on the market and one in late-stage development, comprise the CNS portfolio of Louisville, KY-based US WorldMeds. According to terms of the deal, Supernus … Continue reading “Supernus Makes a Parkinson’s Play With $300M Deal for US WorldMeds Drugs”
Taysha Launches With $30M to Bring Gene Therapy to CNS Disorders
Some former executives and investors behind the second gene therapy to win FDA approval are teaming up again. Their new company, Taysha Gene Therapies, is launching with $30 million in the bank and a plan to bring its first central nervous system (CNS) disorder program into human testing later this year. Taysha is focusing on … Continue reading “Taysha Launches With $30M to Bring Gene Therapy to CNS Disorders”
Xilio Taps Former Tesaro Exec Martin Huber as Chief Medical Officer
Xilio Therapeutics has appointed Martin Huber to serve as its chief medical officer, the same position he held at Tesaro before its 2018 acquisition by GlaxoSmithKline (NYSE: [[ticker:GSK]]). His experience also includes roles at Merck (NYSE: [[ticker:MRK]]), Schering-Plough, Roche, and Rhone-Poulenc Rorer. Waltham, MA-based Xilio is developing antibody cancer drugs designed to activate their cancer-killing … Continue reading “Xilio Taps Former Tesaro Exec Martin Huber as Chief Medical Officer”
AgenTus VP Mark Exley Appointed Chief Scientific Officer of Imvax
Imvax announced that Mark Exley has joined the biotech as its chief scientific officer. Exley comes to Philadelphia-based Imvax from AgenTus Therapeutics, where he was vice president of cellular immunology. His experience also includes faculty positions at Harvard Medical School and the University of Manchester. Imvax’s lead candidate, a tumor cell vaccine called IGV-001, is … Continue reading “AgenTus VP Mark Exley Appointed Chief Scientific Officer of Imvax”
ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans
Last fall, ADC Therapeutics (ADCT) concluded the time just wasn’t right for an IPO. Six months later, with its lead drug in a pivotal test and plans being drawn up for a regulatory submission and potential commercialization, the cancer drug developer has determined it needs cash now. ADCT refiled its IPO plans late Friday. The … Continue reading “ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans”
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
COVID-19’s spread has clamped down on a lot of economic activity, including the work of developing and testing new medicines. But the FDA isn’t showing signs of slowing down, at least when it comes to drugs filed for accelerated approval. The regulator signed off on three such drugs in the past week. These approvals are … Continue reading “Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More”
American Diabetes Association’s Ratner Joins Virta as Chief Medical Officer
Virta Health has appointed Robert Ratner to serve as its chief medical officer. He was most recently the chief scientific & medical officer for the American Diabetes Association. Ratner is also a professor of medicine at Georgetown University Medical School. San Francisco-based Virta has developed software for diabetes patients that provides nutrition information, counseling, and … Continue reading “American Diabetes Association’s Ratner Joins Virta as Chief Medical Officer”
Ex-Bristol Myers Exec Guyer to Join BioMarin, Succeeding Baffi
BioMarin Pharmaceutical (NASDAQ: [[ticker:BMRN]]) has appointed C. Greg Guyer to serve as its chief technical officer and executive vice president of global manufacturing and technical operations. He is scheduled to start on May 4. Guyer was most recently senior vice president of operations at Bristol Myers Squibb (NYSE: [[ticker:BMY]]). At San Rafael, CA-based BioMarin, he will … Continue reading “Ex-Bristol Myers Exec Guyer to Join BioMarin, Succeeding Baffi”
Affinivax Lands $120M to Take MAPS Tech Into New Vaccine Territory
Affinivax has a lead program with early clinical data showing the potential to best a pharmaceutical giant’s blockbuster vaccine. The startup now has $120 million in financing to see just how much further its technology can go. The Series B round of funding announced Thursday was led by Viking Global Investors. Cambridge, MA-based Affinivax develops … Continue reading “Affinivax Lands $120M to Take MAPS Tech Into New Vaccine Territory”